Study Condition(s): Liver Cancer

A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (REACH-2)

Study Alias: JVDE

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02435433 {{ currentLocaleObject.registryAnchorText }}

Study Purpose

The purpose of this study is to evaluate the safety and efficacy of ramucirumab in participants with hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein.

Key Participation Requirements Tool Tip Icon

All clinical trials have rules about who can participate. This section outlines some of those rules. Please contact a study center to discuss the full set of criteria

Gender

Male Female

Age

18+ years

Time Commitment

Your participation in this trial could last up to 3-5 months depending on on how you and your tumor respond
  • Participant must have a confirmed diagnosis of liver cancer or a diagnosis of cirrhosis and a tumor with imaging characteristics of liver cancer

  • Participant must have previously taken sorafenib treatment for at least 14 days

  • Participant must be willing to provide blood for research

  • Female participant must not be pregnant or breastfeeding and must also use highly effective contraceptive method during study participation, if not surgically sterile or postmenopausal

  • Male participant must be surgically sterile or compliant with a highly effective contraceptive method

  • Participant must not have undergone a prior liver transplant

  • Participant must not have uncontrolled hypertension, HIV, AIDS, active or uncontrolled clinically serious infection, ongoing or recent drug abuse, uncontrolled thrombotic or bleeding disorder or a bowel obstruction

Where to Participate

125 locations are currently available of 125 planned
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location Status
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Closest Location to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}}
Other Location(s) to Participate
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
,
Status {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus}} {{site.siteStatus | translate}} {{site.getSiteCTALabel() | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.